Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* relapsed or refractory CLL/SLL~* at least 18 years of age~* able to receive outpatient treatment and follow-up at the treating institution~* completed all CLL therapies \> 4 weeks prior to first study dose~Exclusion Criteria:~* previously treated with an anti-CD19 antibody therapy~* undergone prior allogeneic stem cell transplantation within 6 months or having active graft versus host disease~* active Richter's syndrome~* designated Class III or IV by the New York Heart Association (NYHA) criteria~* history of myocardial infarction or stroke within the last 6 months~* active viral, bacterial, or systemic fungal infection requiring treatment~* HIV or Hepatitis C positive~* Hepatitis B infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): XmAb5574

Based on this trial design, predict the completion outcome and termination type (if applicable).